- Home
- DAWN vs TOVX Comparison
DAWN vs TOVX Comparison
Compare DAWN & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- TOVX
- Stock Information
- Founded
- DAWN 2018
- TOVX 2001
- Country
- DAWN United States
- TOVX United States
- Employees
- DAWN N/A
- TOVX N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- DAWN Health Care
- TOVX Health Care
- Exchange
- DAWN Nasdaq
- TOVX Nasdaq
- Market Cap
- DAWN 658.9M
- TOVX 3.8M
- IPO Year
- DAWN 2021
- TOVX 2006
- Fundamental
- Price
- DAWN $6.63
- TOVX $0.43
- Analyst Decision
- DAWN Strong Buy
- TOVX Hold
- Analyst Count
- DAWN 7
- TOVX 1
- Target Price
- DAWN $31.57
- TOVX N/A
- AVG Volume (30 Days)
- DAWN 1.3M
- TOVX 220.1K
- Earning Date
- DAWN 07-29-2025
- TOVX 08-12-2025
- Dividend Yield
- DAWN N/A
- TOVX N/A
- EPS Growth
- DAWN N/A
- TOVX N/A
- EPS
- DAWN N/A
- TOVX N/A
- Revenue
- DAWN $161,922,000.00
- TOVX N/A
- Revenue This Year
- DAWN $17.98
- TOVX N/A
- Revenue Next Year
- DAWN $49.50
- TOVX N/A
- P/E Ratio
- DAWN N/A
- TOVX N/A
- Revenue Growth
- DAWN N/A
- TOVX N/A
- 52 Week Low
- DAWN $6.08
- TOVX $0.40
- 52 Week High
- DAWN $16.76
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- DAWN 49.20
- TOVX 34.54
- Support Level
- DAWN $6.22
- TOVX $0.42
- Resistance Level
- DAWN $6.95
- TOVX $0.46
- Average True Range (ATR)
- DAWN 0.25
- TOVX 0.03
- MACD
- DAWN 0.03
- TOVX 0.01
- Stochastic Oscillator
- DAWN 57.41
- TOVX 16.83
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.